ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TIVICAY
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TIVICAY Rx

Generic Name and Formulations:
Dolutegravir 10mg, 25mg, 50mg; tabs.

Company:
ViiV Healthcare

Therapeutic Use:

Indications for TIVICAY:

In combination with other antiretroviral agents for the treatment of HIV-1 infection.

Adult:

Treatment-naïve or treatment-experienced INSTI-naïve: 50mg once daily; when concomitant with certain UGT1A or CYP3A inducers: 50mg twice daily. INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50mg twice daily.

Children:

<30kg or INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir): not established. Treatment-naïve or treatment-experienced INSTI-naïve: (30–<40kg): 35mg once daily; (≥40kg): 50mg once daily. If concomitant with certain UGT1A or CYP3A inducers, increase weight-based dose to twice daily.

Contraindications:

Concomitant dofetilide.

Warnings/Precautions:

Discontinue if hypersensitivity reactions develop. Increased risk for worsening/development of elevated transaminases in patients with hepatitis B or C; monitor LFTs prior to starting and during therapy. Severe hepatic impairment: not recommended. INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance) with severe renal impairment: decrease in dolutegravir concentrations may result in loss of efficacy and development of resistance. Dialysis. Elderly. Pregnancy. Nursing mothers: not recommended.

Interactions:

May be affected by drugs that induce or inhibit UGT1A1, UGT1A3, UGT1A9, BCRP, and P-gp enzymes or transporters. Avoid concomitant nevirapine, oxcarbazepine, phenytoin, phenobarbital, St. John’s wort. Avoid etravirine unless coadministered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. Concomitant efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, rifampin, or carbamazepine: adjust dose (see Adults, Children). Concomitant cation-containing antacids, laxatives, sucralfate, oral iron/calcium supplements, and buffered drugs: give dolutegravir 2hrs before or 6hrs after. Limit concomitant metformin dose to 1000mg/day; adjust metformin dose when stopping dolutegravir; monitor closely.

Pharmacological Class:

HIV-1 integrase strand transfer inhibitor (INSTI).

Adverse Reactions:

Insomnia, fatigue, headache; immune reconstitution syndrome, fat redistribution, lab abnormalities, hypersensitivity reactions.

Note:

Register pregnant patients exposed to dolutegravir by calling (800) 258-4263.

Generic Availability:

NO

How Supplied:

Tabs—30

Sign Up for Free e-newsletters